GI
PTCT icon

GAMMA Investing’s PTC Therapeutics PTCT Stock Holding History

GAMMA Investing’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$80.4K Sell
1,241
-212
-15% -$15.4K ﹤0.01% 2040
2026
Q2 		$119K Buy
1,453
+534
+58% +$38.6K ﹤0.01% 1680
2026
Q1 		$62.6K Sell
919
-532
-37% -$37.7K ﹤0.01% 2030
2025
Q4 		$110K Buy
1,451
+893
+160% +$64.9K 0.01% 1503
2025
Q3 		$34.2K Buy
558
+40
+8% +$2.08K ﹤0.01% 2227
2025
Q2 		$25.3K Sell
518
-434
-46% -$20.6K ﹤0.01% 2342
2025
Q1 		$48.5K Buy
952
+441
+86% +$22K ﹤0.01% 1810
2024
Q4 		$23.1K Buy
511
+274
+116% +$11.7K ﹤0.01% 2197
2024
Q3 		$8.79K Buy
237
+126
+114% +$4.22K ﹤0.01% 2516
2024
Q2 		$3.39K Buy
111
+21
+23% +$680 ﹤0.01% 2709
2024
Q1 		$2.62K Buy
90
+23
+34% +$644 ﹤0.01% 2666
2023
Q4 		$1.75K Buy
+67
New +$1.53K ﹤0.01% 2615

Other funds holding PTCT

JWS
Juncture Wealth Strategies Scottsdale, Arizona $390M AUM 19.15% 1-Year Est. Return
PCA
Private Capital Advisors Darien, Connecticut $1.15B AUM 43.46% 1-Year Est. Return
SA
Sacks & Associates Warren, New Jersey $143M AUM 17.48% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
GWM
Gilpin Wealth Management Denver, Colorado $148M AUM 25.13% 1-Year Est. Return
DCM
Davis Capital Management Jacksonville, Florida $167M AUM 17.17% 1-Year Est. Return

GAMMA Investing's PTCT Position: Q3 2026 in Review

GAMMA Investing reduced its PTC Therapeutics (PTCT) stake by 15% in Q3 2026, selling an estimated $15.4K and leaving 1,241 shares worth $80.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2040.

GAMMA Investing first reported a position in PTCT in Q4 2023 and has held it in 12 quarters since. The position peaked at $119K in Q2 2026. 8 funds tracked by Wall St. Rank hold PTCT as of Q3 2026.

  • GAMMA Investing held 1,241 shares of PTC Therapeutics worth $80.4K as of Q3 2026.
  • GAMMA Investing sold 212 PTC Therapeutics shares in Q3 2026, an estimated $15.4K.
  • PTC Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #2040 holding.
  • GAMMA Investing first reported a position in PTC Therapeutics in Q4 2023 and has held it in 12 quarters since.
  • GAMMA Investing's PTC Therapeutics position peaked at $119K in Q2 2026.
  • 8 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.